Page last updated: 2024-09-04

tariquidar and Cancer of Ovary

tariquidar has been researched along with Cancer of Ovary in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Charlton, PA; Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, SJ; Mills, L; Norris, D; Prin, A; Sharma, S; Whitehouse, PA	1
Sarisozen, C; Torchilin, VP; Zou, W	1
Balis, FM; Bates, SE; Chen, CC; Chen, X; Draper, D; Figg, WD; Fojo, T; Gardner, ER; Kelly, RJ; Piekarz, RL; Robey, RW; Steinberg, SM; Venkatesan, AM	1

Trials

1 trial(s) available for tariquidar and Cancer of Ovary

Article	Year
A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Quinolines; Taxoids; Uterine Cervical Neoplasms	2011

Article

Year

A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Feb-01, Volume: 17, Issue:3

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Docetaxel; Female; Humans; Lung Neoplasms; Middle Aged; Ovarian Neoplasms; Quinolines; Taxoids; Uterine Cervical Neoplasms

2011

Other Studies

2 other study(ies) available for tariquidar and Cancer of Ovary

Article	Year
Ex vivo reversal of chemoresistance by tariquidar (XR9576). Anti-cancer drugs, 2004, Volume: 15, Issue:9 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Quinolines; Skin Neoplasms; Tumor Cells, Cultured	2004
The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles. Journal of drug targeting, 2017, Volume: 25, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Multiple; Female; Humans; Micelles; Ovarian Neoplasms; Paclitaxel; Polymers; Quinolines	2017

Article

Year

Ex vivo reversal of chemoresistance by tariquidar (XR9576).

Anti-cancer drugs, 2004, Volume: 15, Issue:9

Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Male; Middle Aged; Ovarian Neoplasms; Quinolines; Skin Neoplasms; Tumor Cells, Cultured

2004

The reversal of multidrug resistance in ovarian carcinoma cells by co-application of tariquidar and paclitaxel in transferrin-targeted polymeric micelles.

Journal of drug targeting, 2017, Volume: 25, Issue:3

Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Multiple; Female; Humans; Micelles; Ovarian Neoplasms; Paclitaxel; Polymers; Quinolines

2017